Companies › GT Medical Technologies
1 active drug program in 2 registered trials: 1 Phase 4, 1 Phase 3; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GammaTile (Cs-131 brachytherapy) Cs-131 embedded in bioresorbable collagen tiles for focal brachytherapy | – | Phase 4 | Glioblastoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05342883 | GammaTile (Cs-131 brachytherapy) | Phase 4 | Glioblastoma | Oncology | Dec 2027 |
| NCT07195591 | GammaTile (Cs-131 brachytherapy) | Phase 3 | Glioblastoma | Oncology | Dec 2031 |
No annotated target.
–
Lakefront Biotherapeutics Suzhou Immunofoco Biotechnology Biofrontera CG Oncology CNBG-Virogin Biotech (Shanghai)
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.